Guillermo Ramil

Guillermo Ramil

Auto-generated profile, based on publicly available information

Guillermo Ramil

Department of Medicine Universitat Autonoma of Barcelona. Hospital de la Santa Creu i Sant Pau (IR Sant Pau). Institut Josep Carreras Barcelona Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
CJCarlos Jimenez-Vicente
Carlos Jimenez-Vicente
ACAina Cardus
Aina Cardus
Sandra Castaño DíezSandra Castaño Díez
Sandra Castaño Díez
GRGuillermo Ramil
Guillermo Ramil
SGSara Garcia-Avila
Sara Garcia-Avila
OGon behalf of the Spanish CETLAM Group
on behalf of the Spanish CETLAM Group
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with

14 October 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
HCHelena Castellet
Helena Castellet
AGAnna Giné‐Vilalta
Anna Giné‐Vilalta
MPMarta Pratcorona
Marta Pratcorona
GRGuillermo Ramil
Guillermo Ramil
GOGuadalupe Oñate
Guadalupe Oñate
JNJosep Nomdedéu
Josep Nomdedéu

23 June 2026 in Blood Advances
Verified
Journal Article
Open access
STSara Torres-Esquius
Sara Torres-Esquius
GRGuillermo Ramil-López
Guillermo Ramil-López
MGMaria Gabarrós-Subirà
Maria Gabarrós-Subirà
MDMarin Diaz-Beya
Marin Diaz-Beya
EREugènia Rivero
Eugènia Rivero
MMMaria Julia Montoro
Maria Julia Montoro

2 November 2026 in European Journal of Haematology
Verified
Journal Article
Open access
GRGuillermo Ramil
Guillermo Ramil
EBElena Bussaglia
Elena Bussaglia
HCHelena Castellet
Helena Castellet
GOGuadalupe Oñate
Guadalupe Oñate
AGAna Garrido
Ana Garrido
JNJosep F. Nomdedeu
Josep F. Nomdedeu
Background: Isocitrate dehydrogenase ( IDH ) mutations are recurrent in acute myeloid leukemia (AML) and represent promising targets for measurable residual disease (MRD) monitoring. However, clinically validated strategies for IDH ‐based MRD assessment remain lacking. Methods: We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single‐center cohort of patients with IDH ‐mutated AML treated with curative intent. Healthy controls were included to characterize low‐level background signals and identify a clinical threshold. Results: ddPCR showed robust analytical performance, with a limit of detection of 0.01% variant allele frequency (VAF) and strong concordance with NGS. Low‐level IDH mutation signals were frequently detected in healthy individuals and in patients in remission. We identified 0.2% VAF as a candidate threshold for clinically relevant IDH MRD. Using this cutoff, post‐treatment detectable IDH MRD was associated with a higher 2‐year cumulative incidence of relapse (63.6% vs. 20%; p = 0.019) and inferior overall survival (70.6% vs. 92.9%; p = 0.04). Among patients negative by multiparameter flow cytometry, ddPCR identified residual IDH‐ mutated clones in 56% of cases, who showed higher relapse rates than double‐negative patients (50% vs. 0%; p = 0.031). Conclusions: A 0.2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH ‐based MRD assessment in AML.

26 October 2026 in Blood
Verified
Journal Article
Closed access
MGMaria Gabarros-Subira
Maria Gabarros-Subira
HPHelena Pomares
Helena Pomares
FBFrancisco Beas
Francisco Beas
STSara Torres-Esquius
Sara Torres-Esquius
MLMiguel López-Esteban
Miguel López-Esteban
AJAndrés Jerez
Andrés Jerez
Donor cell-derived hematologic neoplasm (DDHN) is defined as a de novo hematologic malignancy originated from transplanted donor stem cells, distinct from the original recipient's disease (ORD). Its prevalence and biological mechanisms remain poorly defined. We conducted a nationwide study to estimate the prevalence of DDHN and characterize its clinical and molecular features. Twenty-four transplantation centers systematically reviewed their allogeneic hematopoietic stem cell transplantation (allo-HSCT) cohorts. DDHN diagnosis required cytogenetic or molecular donor-origin confirmation. Molecular studies included germline-augmented targeted NGS, whole-exome sequencing, and donor-recipient comparative analyses. We identified 39 DDHN cases diagnosed between 2007 and 2025. Among 8,465 allo-HSCT performed between 2013-2022, DDHN prevalence was 0.28%, with a marked predominance after related-donor compared with unrelated transplantation (0.41% vs. 0.06%, p=0.0026). Median latency from transplantation to DDHN diagnosis was 56 months. Most DDHN were myeloid neoplasms, predominantly myelodysplastic neoplasms (51%) and acute myeloid leukemia (36%). Molecular characterization, available in 33 cases, revealed germline predisposition as the predominant underlying mechanism. Pathogenic/likely pathogenic germline variants were identified in 10 cases, involving DDX41 (n=7), CEBPA (n=2), and CHEK2 (n=1), all after a related-donor transplantation. DDX41-associated DDHN showed recurrent somatic hits and low genomic complexity. Donor-derived clonal hematopoiesis was confirmed in only one myeloid case involving U2AF1. These findings support inherited germline predisposition as the potential main molecular driver of DDHN after related allo-HSCT, reinforcing the recommendation for comprehensive germline evaluation of patients at ORD diagnosis prior to transplantation, followed by targeted cascade screening of candidate related donors.

29 October 2026 in Blood Advances
Verified
Journal Article
Closed access
LPLaura Palomo
Laura Palomo
MMMireia Morgades
Mireia Morgades
MMManja Meggendorfer
Manja Meggendorfer
MDMarina Díaz-Beyá
Marina Díaz-Beyá
HPHelena Pomares
Helena Pomares
BXBlanca Xicoy
Blanca Xicoy
Prognostication in chronic myelomonocytic leukemia (CMML) remains a challenge because of the biological complexity and variable clinical course of the disease. This study aimed to evaluate the prognostic utility of the Molecular International Prognostic Scoring System (IPSS-M) in CMML and its applicability across the myelodysplastic (MD) and myeloproliferative (MP) subsets of the disease. We conducted a multicenter, retrospective study including 511 patients diagnosed with CMML. Clinical, cytogenetic, and molecular data were collected at diagnosis, including targeted next-generation sequencing. Patients were stratified using IPSS-M, the molecular CMML-specific prognostic scoring system (CPSS-Mol), and the recently developed international CPSS (iCPSS). IPSS-M effectively stratified patients into risk groups with significantly different overall survival (OS) and cumulative incidence of acute myeloid leukemia (AML) progression. Discrimination was maintained after merging overlapping intermediate-risk categories, yielding a 4-tier model with a C-index of 0.678 for OS and 0.628 for AML progression, respectively. This model retained its prognostic performance in both MD-CMML and MP-CMML subsets, with a higher discrimination for OS in the MD-CMML group. When compared with CPSS-Mol and iCPSS, adapted IPSS-M showed comparable prognostic performance to iCPSS and improved discrimination compared with CPSS-Mol. These findings support the applicability of an adapted IPSS-M to CMML, extending its use beyond myelodysplastic syndromes and highlighting its potential utility in guiding clinical decision-making and therapeutic strategies. Moreover, this study provides an external validation of the iCPSS in an independent and genetically well-characterized CMML cohort, reinforcing its clinical utility.